SCHEMBL25755475

SCHEMBL25755475

CC(C)(C)OC(=O)NCCCOCCOCCCl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.54
MEN1 O00255 1/20 0.51
GAA P10253 1/20 0.51
KMT2A Q03164 1/20 0.51
CA12 O43570 7/20 0.49
CA1 P00915 7/20 0.49
CA2 P00918 7/20 0.49
CA9 Q16790 7/20 0.49
MAOA P21397 1/20 0.48
MAOB P27338 1/20 0.48
EPHX1 P07099 1/20 0.42
STK17B O94768 1/20 0.41
STK17A Q9UEE5 1/20 0.41
HTT P42858 1/20 0.39
DRD2 P14416 1/20 0.38
CYP1A1 P04798 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2B6 P20813 1/20 0.38
CYP2C19 P33261 1/20 0.38
CYP3A43 Q9HB55 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21065333 0.92 TDP1 (0.62) TDP1MEN1GAAKMT2ACA12
SCHEMBL25756212 0.90 TDP1 (0.54) TDP1MEN1GAAKMT2ACA12
SCHEMBL463171 0.89 TDP1 (0.53) TDP1MEN1GAAKMT2ACA12
SCHEMBL25756347 0.89 TDP1 (0.57) TDP1MEN1GAAKMT2ACA12
SCHEMBL31614625 0.88 TDP1 (0.49) TDP1MEN1GAAKMT2ACA12
SCHEMBL22911493 0.87 TDP1 (0.54) TDP1MEN1GAAKMT2ACA12
SCHEMBL25770346 0.87 TDP1 (0.58) TDP1MEN1GAAKMT2ACA12
SCHEMBL31614631 0.87 TDP1 (0.48) TDP1MEN1GAAKMT2ACA12
SCHEMBL24391005 0.86 TDP1 (0.50) TDP1MEN1GAAKMT2ACA12
SCHEMBL22508013 0.86 TDP1 (0.50) TDP1MEN1GAAKMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 TDP1 1380/4885MEN1 940/4885GAA 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.